STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Karo Bio (STO:KARO) has received approval for initiation of a phase IIb clinical study with KB2115. This study will be conducted in dyslipidemia patients receiving concomitant statin treatment. Patient recruitment has been initiated for the three month study which in total will include 172 patients.
Elevated blood lipids significantly correlate with development of cardiovascular disease. In particular high plasma levels of the harmful LDL-cholesterol contribute to disease development. There is a great need for new dyslipidemia drugs that can be used together with statins since a significant part of the patients do not reach the treatment goals on single therapy.
